Editorially independent content, supported with advertising
09.30.22
What changed in the most recent iteration of the International Classification of Retinopathy of Prematurity? And what do new data tell us about how ROP patients fare in adulthood? To find out, Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to break down the latest literature, examine the papers' limitations, and offer pearls for surgical management of adults with history of ROP.
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
06.20.25
Photobiomodulation for Age-related Macular DegenerationModerator Barton Blackorby, MD; Hong-Uyen Hua, MD; and Louis Cai, MD
03.21.25
Rates of Ocular AEs After Faricimab InjectionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
12.19.24
Switching from Aflibercept to Faricimab in Wet AMD PatientsBen Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,
11.21.24
New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?Moderator Rebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
10.17.24
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis PreventionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
09.17.24
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAOKatherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD
08.29.24
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF TherapyBen Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD,
07.19.24
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol ACRebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
Show More